About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR
  Press Releases
  Media Stories
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts

Press Releases

2017 2018 2019
2016 2015 2014 2013 2012 2011
2010 2009 2008 2007 2006 2005

  December 2017
29 Dec Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs Download Pdf
13 Dec Company Statement : Biocon’s Clarification post media reports on “Biocon on the FDA list for not paying facility fee.”
Biocon has paid Facility Fee for its API facility to USFDA in Sep 2017
Download Pdf
01 Dec U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers Download Pdf
01 Dec European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim Download Pdf
  November 2017
23 Nov Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India Download Pdf
20 Nov Company Statement : Biocon's Drug Product Facility Receives EIR with VAI status, Inspection Closed Download Pdf
07 Nov Company Statement on Resubmission of Biosimilar Trastuzumab and Pegfilgrastim Dossiers with EMA Download Pdf
  October 2017
26 Oct Biocon Q2FY18 Press Release Download Pdf
25 Oct Biocon Ranked Among Top 10 Global Pharma & Biotech Employers Download Pdf
10 Oct Company Statement : US FDA Issues Complete Response Letter for Proposed Biosimilar Pegfilgrastim Download Pdf
06 Oct Company Statement : No Separate Audit or Observations by Health Canada Download Pdf
  September 2017
18 Sept Biocon's Facility in Vishakhapatnam completes US FDA Inspection with no observations Download Pdf
07 Sept Biocon´s Insulins facility in Malaysia Receives EU GMP Compliance Certificate Download Pdf
06 Sept JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment Download Pdf
  August 2017
30 Aug USFDA Target Action Date for Trastuzumab Reset to December 3, 2017 Download Pdf
16 Aug Company Statement on Status of EMA Dossiers Download Pdf
03 Aug Company Statement on USFDA Visit in May/June2017. CAPA is under Implementation Download Pdf
  July 2017
27 Jul Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore, Net Profit at Rs 81 Crore Download Pdf
14 Jul FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab Download Pdf
09 Jul Biocon Statement on ANSM Inspection Report Download Pdf
  June 2017
11 Jun Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions Download Pdf
05 Jun Biocon Appoints Ms. Pratima Rao as Mission Director of Biocon Foundation Download Pdf
  May 2017
10 May Company Statement on Media Reports on USFDA 483s Download Pdf
05 May Kiran Mazumdar-Shaw Felicitated with 'AWSM Award for Excellence 2017' by The Feinstein Institute for Medical Research, USA Download Pdf
  April 2017
27 Apr  Biocon Q4 FY17 Revenue Rs 974 Cr; Net  Profit Rs 127 Cr; FY17 Revenue at Rs 4,079  Cr; Net Profit at Rs 612 Cr Download Pdf
  February 2017
16 Feb  U.S. FDA Accepts Biologics License  Application (BLA) for Mylan and Biocon's  Proposed Biosimilar Pegfilgrastim for Review Download Pdf
07 Feb  Biocon Foundation & Department of Medical,  Health & Family Welfare, Govt. of Karnataka  Collaborate to Set Up Smart eLAJ Clinics in  Karnataka Download Pdf
  January 2017
25 Jan  Biocon Wins MYR 300 Million Contract for  Insulin from MoH, Malaysia Download Pdf
24 Jan  Biocon Q3 FY17 Net Profit Up 65% at Rs 171  Crore Revenue Rises 32% at Rs 1092  Crore; EBITDA Increases 57% to Rs 324  Crore Download Pdf
11 Jan  U.S. FDA Accepts Biologics License  Application (BLA) for Mylan and Biocon's  Proposed Biosimilar Trastuzumab Download Pdf


Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved